BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting

Reuters

16 Jun

BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting

June 16 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:

MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETING
MILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYS
MILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSION
MILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETING

Source text: ID:nGNX3T4VhX

Further company coverage: MIST.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2543467258"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543467258\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543467258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543467258","market":"nz","top_or_hot":-1,"title":"BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting</title></head><body><p><span>June 16 (Reuters)</span><span> - </span>Milestone Pharmaceuticals Inc <span>MIST.O</span>:</p><ul><li><p>MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETING</p></li><li><p>MILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYS</p></li><li><p>MILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSION</p></li><li><p>MILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETING</p></li></ul><p>Source text: <span>ID:nGNX3T4VhX</span></p><p>Further company coverage: <span>MIST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting</title></head><body><p><span>June 16 (Reuters)</span><span> - </span>Milestone Pharmaceuticals Inc <span>MIST.O</span>:</p><ul><li><p>MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETING</p></li><li><p>MILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYS</p></li><li><p>MILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSION</p></li><li><p>MILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETING</p></li></ul><p>Source text: <span>ID:nGNX3T4VhX</span></p><p>Further company coverage: <span>MIST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nTUA3BBJY7:1","article_id":"2543467258","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543467258","pubTimestamp":1750075533,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A MeetingJune 16 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:MILEST","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BRIEF-Milestone Pharmaceuticals在A型会议后提交了对FDA治疗PSVT的CARDAMYST（Etripamil）鼻喷雾剂CRL的回应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIST":0.9},"content_text":"BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A MeetingJune 16 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETINGMILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYSMILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSIONMILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETINGSource text: ID:nGNX3T4VhXFurther company coverage: MIST.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}